DOKTER LILIANE LOMBAERT , ALGEMENE GENEESKUNDE
0821.670.073 · rovalta.com · 27/09/2026
DOKTER LILIANE LOMBAERT , ALGEMENE GENEESKUNDE
Company — Normal situation.
Strike-off: 03 juillet 2026
Financial year 2026 · Closed on 24/06/2026
Overview
Identity
Source · BCE/KBODOKTER LILIANE LOMBAERT , ALGEMENE GENEESKUNDE is a Private company with limited liability incorporated in 2009.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0821.670.073
- Incorporation
- 22/12/2009
- Legal form
- Private company with limited liability
- Contributed capital
- 12 400,00 €
- Latest accounts
- 24/06/2026
Financials
Source · NBB, 17 filingsTrend over 17 financial years
| 2026 | 2025 | 2024 | 2023 | 2022 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 14 k € | -91.4% | 162,2 k € | -5.8% | 172,2 k € | +31.9% | 130,6 k € | +3.8% | 125,7 k € |
| EBITDA | 10,9 k € | -93.3% | 162 k € | -5.1% | 170,7 k € | +32.2% | 129,1 k € | +3.5% | 124,7 k € |
| Operating result | 10,9 k € | -92.8% | 151,1 k € | -6.6% | 161,9 k € | +36.8% | 118,3 k € | +4.1% | 113,6 k € |
| Net result | 150,1 k € | +43.8% | 104,4 k € | -2.7% | 107,2 k € | +36.9% | 78,3 k € | +1.6% | 77,1 k € |
| Balance sheet | |||||||||
| Equity | 701,7 k € | +27.2% | 551,6 k € | +23.3% | 447,2 k € | +31.5% | 340 k € | +29.9% | 261,7 k € |
| Total assets | 701,7 k € | +17.0% | 599,7 k € | +21.8% | 492,5 k € | +25.3% | 393,1 k € | +22.2% | 321,7 k € |
| Cash | 54,6 € | -99.9% | 67,7 k € | -13.7% | 78,4 k € | +65.2% | 47,5 k € | +81.5% | 26,2 k € |
| Debts | – | 45,5 k € | +9.1% | 41,7 k € | -16.7% | 50 k € | -16.7% | 60 k € | |
Board of directors
Source · NBB, accounts to 24/06/20261 active · 5 ended
Active mandates
Ended mandates
Financials
Full financial information
Source · NBB| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2026 | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 |
| Closing of the financial year | 24/06/2026 | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Length of the financial year | 6 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 07/07/2026 | 18/05/2026 | 02/06/2025 | 04/06/2024 | 14/06/2023 | 25/07/2022 |
| General meeting | 24/06/2026 | 13/05/2026 | 28/05/2025 | 29/05/2024 | 31/05/2023 | 25/05/2022 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 17 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 24/06/2026 | 24/06/2026 | 07/07/2026 | Dutch | |
| Micro model | 31/12/2025 | 13/05/2026 | 18/05/2026 | Dutch | |
| Micro model | 31/12/2024 | 28/05/2025 | 02/06/2025 | Dutch | |
| Micro model | 31/12/2023 | 29/05/2024 | 04/06/2024 | Dutch | |
| Micro model | 31/12/2022 | 31/05/2023 | 14/06/2023 | Dutch | |
| Micro model | 31/12/2021 | 25/05/2022 | 25/07/2022 | Dutch | |
| Micro model | 31/12/2020 | 26/05/2021 | 23/06/2021 | Dutch | |
| Micro model | 31/12/2019 | 27/05/2020 | 27/07/2020 | Dutch | |
| Micro model | 31/12/2018 | 29/05/2019 | 24/06/2019 | Dutch | |
| Micro model | 31/12/2017 | 30/05/2018 | 23/07/2018 | Dutch | |
| Micro model | 31/12/2016 | 31/05/2017 | 29/08/2017 | Dutch | |
| Abridged model | 31/12/2015 | 25/05/2016 | 25/07/2016 | Dutch | |
| Abridged model | 31/12/2014 | 27/05/2015 | 21/08/2015 | Dutch | |
| Abridged model | 31/12/2013 | 28/05/2014 | 25/07/2014 | Dutch | |
| Abridged model | 31/12/2012 | 29/05/2013 | 23/07/2013 | Dutch | |
| Abridged model | 31/12/2011 | 30/05/2012 | 02/07/2012 | Dutch | |
| Abridged model | 31/12/2010 | 25/05/2011 | 06/06/2011 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 24/06/20261 active · 5 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for freePublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2026Annual accounts 2026150,1 k €↑
- 2025Annual accounts 2025104,4 k €↓
- 2024Annual accounts 2024107,2 k €↑
- 2023Annual accounts 202378,3 k €↑
- 2023Name changeDokter Liliane Lombaert, algemene geneeskunde
- 2022Annual accounts 202277,1 k €↑
- 2021Annual accounts 202173 k €↑
- 2021Name changeLOMBAERT LILIANE
- 2020Annual accounts 202039,1 k €↑
- 2019Annual accounts 201919,4 k €↑
- 2018Annual accounts 201812,5 k €↑
- 2017Annual accounts 20173,1 k €↓
- 2016Annual accounts 20168,1 k €↓
- 2015Annual accounts 20159,3 k €↑
- 2014Annual accounts 20141,9 k €↓
- 2013Annual accounts 20137,5 k €↑
- 2012Annual accounts 20122,7 k €↑
- 2011Annual accounts 2011-2,8 k €↓
- 2010Annual accounts 20105,5 k €
- 22/12/2009IncorporationPrivate company with limited liability